Onsdag 30 Oktober | 09:26:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-10-22 - Kvartalsrapport 2025-Q3
2025-07-18 - Kvartalsrapport 2025-Q2
2025-04-29 - Kvartalsrapport 2025-Q1
2025-04-29 - Årsstämma
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2024-04-05 08:00:00

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. SEE ALSO THE SECTION ”IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.

The final outcome of the rights issue in Vimian Group AB (publ) ("Vimian") of up to approximately SEK 1,633 million (the “Rights Issue”) shows that 60,940,208 ordinary shares have been subscribed for with subscription rights. The remaining 4,362,416 ordinary shares have been allotted to those who have subscribed for ordinary shares without subscription rights. Approximately 137 per cent of the Rights Issue has been subscribed for. The Rights Issue is thus oversubscribed, and Vimian will receive proceeds amounting to approximately SEK 1,633 million before issue costs.

  • The outcome shows that 60,940,208 ordinary shares, corresponding to approximately 93 per cent of the shares offered in the Rights Issue, have been subscribed for with subscription rights. The remaining 4,362,416 ordinary shares that were not subscribed for with subscription rights have been allocated to those who have subscribed for shares without subscription rights in accordance with the principles set out in the prospectus. The outcome shows that approximately 137 per cent of the Rights Issue has been subscribed for. The Rights Issue is thus oversubscribed and the guarantee undertaking from Vimian's largest shareholder Fidelio Vet Holding AB will not be utilized.
  • As confirmation of allotment of ordinary shares subscribed for without subscription rights, a settlement note will be sent to those who have been allotted ordinary shares, which is expected to be made on 5 April 2024. No notice will be sent to those who have not been allotted ordinary shares. Subscribed and allotted shares shall be paid for in cash in accordance with the instructions on the settlement note. Nominee-registered shareholders will receive notice of allotment and payment in accordance with the procedures of the respective nominee.
  • Vimian will through the Rights Issue receive proceeds amounting to approximately SEK 1,633 million before issue costs. Through the Rights Issue, Vimian's share capital will increase with SEK 108,902.337580, from SEK 762,316.373064 to SEK 871,218.710644 by the issue of 65,302,624 new ordinary shares. The number of shares in Vimian after the Rights Issue will amount to 522,420,998 (of which 509,542,790 ordinary shares and 12,878,208 class C shares).
  • The last day of trading in paid subscription shares (BTA) is 10 April 2024. The new ordinary shares subscribed for with and without subscription rights are expected to start trading at Nasdaq First North Growth Market from and including 16 April 2024.
  • Vimian intends to use the net proceeds from the Rights Issue to act on value-creative acquisition opportunities in the near term.

Advisors
Carnegie Investment Bank AB (publ) and DNB Markets, a part of DNB Bank ASA, Sweden Branch, are Joint Global Coordinators and Joint Bookrunners and Advokatfirman Vinge KB is legal advisor to Vimian in connection with the rights issue.